1. Introduction {#sec1-nutrients-11-01456}
===============

Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease, with a characteristic feature of aberrant responses in the innate and adaptive immune system \[[@B1-nutrients-11-01456]\]. These abnormalities in the immune system contribute to the development of autoimmunity in SLE, damaging various organs. Regarding the organs involved in SLE, lupus nephritis (LN) is one of the most serious complications which is associated with a high morbidity and mortality \[[@B2-nutrients-11-01456]\]. It is estimated that, during the course of SLE, nearly 60% of patients develop LN, among whom 10% eventually develop end-stage renal failure (ESRF) \[[@B3-nutrients-11-01456],[@B4-nutrients-11-01456]\]. Therefore, it is important to identify patients highly susceptible to ESRF. The ultimate goal in treating LN is to prevent ESRF through appropriate immunosuppressive treatment. Accordingly, numerous efforts have been made to discover the factors associated with patient prognosis in LN.

In general, malnutrition is considered to be a condition associated with increased morbidity and mortality \[[@B5-nutrients-11-01456]\]. Meanwhile, compromised nutritional status was reported to be associated with chronic inflammation as well as the development of autoimmunity \[[@B6-nutrients-11-01456]\]. Therefore, investigations have been made to elucidate the prognostic implication of the nutritional status in various diseases. Interestingly, some studies have indicated that abnormalities in the nutritional status are associated with a poor prognosis in malignancies, as well as autoimmune diseases, such as rheumatoid arthritis (RA) and systemic sclerosis. This suggests that assessment of malnutrition could provide clinically valuable information regarding patient prognosis \[[@B7-nutrients-11-01456],[@B8-nutrients-11-01456],[@B9-nutrients-11-01456]\].

Traditionally, anthropometric measures, such as the height or body mass index (BMI) or laboratory tests, i.e., albumin, prealbumin, and total cholesterol level in the blood, have been used to assess the individual's nutritional status \[[@B10-nutrients-11-01456],[@B11-nutrients-11-01456]\]. Nonetheless, because there is no common consensus regarding the most useful tool to assess the nutritional status, inconsistencies abound regarding the prognostic implication of nutritional status in various diseases. Recently, mini-nutritional indices including the controlling nutritional status (CONUT) score, prognostic nutritional index (PNI), nutritional risk index (NRI), and neutrophil-to-lymphocyte ratio (NLR) have also been increasingly used as surrogate markers to reflect the patients' nutritional status \[[@B12-nutrients-11-01456],[@B13-nutrients-11-01456],[@B14-nutrients-11-01456]\]. Given that SLE is a representative systemic inflammatory autoimmune disease, it could be speculated that nutritional indices at diagnosis could be associated with patient prognosis in SLE. However, the predictive potential of nutritional indices for the prognosis of LN is still unknown. Hence, the aim of this study was to (i) investigate the association between 5 different nutritional indices with disease activity, and (ii) evaluate whether these nutritional indices are associated with the development of ESRF in patients with biopsy-proven LN during the follow-up.

2. Materials and Methods {#sec2-nutrients-11-01456}
========================

2.1. Patient Inclusion {#sec2dot1-nutrients-11-01456}
----------------------

The medical records of 260 patients who had undergone renal biopsy between August 2005 and August 2018 and were diagnosed with LN were reviewed. From the 260 patients included, this study excluded 53 for the following reasons: (i) Patients who did not fulfil the 1997 revised American College of Rheumatology (ACR) classification criteria for SLE \[[@B15-nutrients-11-01456],[@B16-nutrients-11-01456]\]; (ii) patients with histopathologic findings incompatible to the criteria proposed by the 2003 International Society of Nephrology/Renal Pathology Society (ISN/RPS) \[[@B17-nutrients-11-01456],[@B18-nutrients-11-01456]\]; (iii) in LN patients who had undergone repeat renal biopsy, only the result of the first biopsy was used. Finally, a total of 207 patients were included. This study was approved by the Institutional Review Board of Severance Hospital and conducted in accordance with the principles set forth in the Declaration of Helsinki, and the requirement to obtain informed consent was waived because of the retrospective study design (4-2018-1083).

2.2. Clinical and Laboratory Data Collection {#sec2dot2-nutrients-11-01456}
--------------------------------------------

The authors obtained the clinical and laboratory data of the date when the pathologic diagnosis of LN was made. The demographic data collected included age and sex. For SLE activity-related measures, the following were evaluated: The SLE disease activity index-2000 (SLEDAI-2K); white blood cell (WBC) and platelet counts; the levels of complement (C)3, C4, and anti-dsDNA; and the urinary protein/creatinine ratio (P/Cr), which is a laboratory component of SLEDAI-2K \[[@B19-nutrients-11-01456]\]. The clinical features of patients consisted of skin rashes, photosensitivity, oral ulcers, arthritis, serositis, neurologic, hematologic, and immunologic disorders, according to the 1997 ACR classification criteria \[[@B15-nutrients-11-01456]\]. Other laboratory data included lymphocyte count, erythrocyte sedimentation rate (ESR), and levels of C-reactive protein (CRP), creatinine, total cholesterol, serum albumin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT). The glomerular filtration rate (GFR) was calculated by the chronic kidney disease epidemiology collaboration study equation \[[@B20-nutrients-11-01456]\]. Concerning renal biopsy data, the class of LN as well as the activity and chronicity indices were assessed based on the 2003 ISN/RPS classification criteria. The medication usage after the diagnosis of LN was assessed using the Korean drug utilization system.

2.3. Nutritional Indices Selection and Calculation {#sec2dot3-nutrients-11-01456}
--------------------------------------------------

Five different measures of nutritional indices were included in the study: CONUT score, PNI, NRI, NLR, and BMI. The calculations of CONUT score, PNI, NRI, NLR, and BMI were performed according to the following formulae: (i) CONUT score is the sum of serum albumin score, total lymphocyte count score, and total cholesterol score based on a predefined cut-off ([Supplementary Table S1](#app1-nutrients-11-01456){ref-type="app"}) \[[@B21-nutrients-11-01456]\]; (ii) PNI is 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (/mm^3^) \[[@B22-nutrients-11-01456]\]; (iii) NRI is (1.519 × serum albumin (g/dL)) + (41.7 × weight (kg)/ideal body weight (kg)) \[[@B13-nutrients-11-01456]\]; (iv) NLR is the total neutrophil count in the peripheral blood/total lymphocyte count in the peripheral blood (/mm^3^) \[[@B23-nutrients-11-01456]\]; (v) BMI is weight (kg)/height (m^2^). Being overweight was defined as a BMI of over 23.0, in accordance with the Asia-Pacific guidelines of obesity classification \[[@B24-nutrients-11-01456]\].

2.4. Statistical Analysis {#sec2dot4-nutrients-11-01456}
-------------------------

All statistical analyses were performed using MedCalc statistical software version 18.11 (MedCalc Software, Ostend, Belgium). The continuous variables were presented as median and interquartile ranges, and categorical variables were presented as frequencies and percentages. For the comparison of continuous and categorical variables, the Mann-Whitney U test and Kruskal-Wallis test, and the chi-square or Fisher's exact test were used as appropriate. The correlation between nutritional indices and variables were assessed using the Pearson's correlation analysis. Low and high PNI was defined using receiver operating characteristics (ROC) curve and patients with PNI ≤35.41 were classified as having low PNI, while patients with PNI \>35.41 were classified as having high PNI. Kaplan-Meier analysis was used to compare the renal survival rate of patients with low and high PNI. Univariable and multivariable Cox-proportional hazard analysis was used to evaluate factors associated with ESRF. In all statistical analysis, a two-tailed *p* \< 0.05 was considered to be significant.

3. Results {#sec3-nutrients-11-01456}
==========

3.1. Clinical Characteristics of Patients {#sec3dot1-nutrients-11-01456}
-----------------------------------------

The baseline characteristics of patients included in the study are described in [Table 1](#nutrients-11-01456-t001){ref-type="table"}. The median age was 36.0 years and 186 (89.9%) of the patients were female. The median follow-up duration was 57.1 months. When the patients were divided into those with and without ESRF during the follow-up, 20 (9.7%) were classified as having ESRF, while 187 (90.3%) were classified as without. Regarding SLE activity-related measures, the patients with ESRF had significantly lower platelet counts and anti-dsDNA titres. There was no significant difference in the clinical features between the groups. In addition, the patients with ESRF presented with lower lymphocyte counts and GFR but higher creatinine levels at diagnosis. For renal biopsy data, mixed class V LN was observed more frequently in patients without ESRF, whereas the chronicity index was significantly higher in patients with ESRF. In addition, when the authors compared the nutritional indices between the groups, differences were found only in PNI, and patients with ESRF had significantly lower PNI than those without (median PNI 31.1 vs. 34.7, *p* = 0.012). No significant differences were noted regarding the medications that were administered in both groups during the follow up ([Supplementary Table S2](#app1-nutrients-11-01456){ref-type="app"}).

3.2. Correlation between Variables and Nutritional Indices {#sec3dot2-nutrients-11-01456}
----------------------------------------------------------

When the association between variables and nutritional indices were evaluated, SLE disease activity-related measures, such as SLEDAI-2K, WBC and platelet count, C3, C4, and anti-dsDNA levels, and urinary P/Cr ratio, were significantly correlated with the CONUT score and PNI. SLEDAI-2K had the highest correlation with CONUT score, followed by PNI (*r* = 0.467, and *r* = −0.356, all *p* \< 0.001). Although SLEDAI-2K and C3 were correlated with NRI, the association was weak. Moreover, significant correlations between the WBC count and the NLR were found, and urinary P/Cr ratio was associated with BMI among SLE activity-related measures ([Table 2](#nutrients-11-01456-t002){ref-type="table"}).

Concerning other variables, the lymphocyte count was significantly correlated with the CONUT score, PNI, and NLR. The CRP was significantly correlated with the CONUT score, PNI, NLR, and BMI. Creatinine levels only correlated with PNI, while GFR only correlated with BMI. The total cholesterol level was correlated with the PNI, NLR, and BMI and the serum albumin level was found to be correlated with the CONUT score, PNI, and NRI. Lastly, AST level was correlated only with the CONUT score and the activity index seen on renal biopsy was correlated only with the CONUT score and PNI ([Table 2](#nutrients-11-01456-t002){ref-type="table"}). On evaluating the associations with the nutritional indices, the CONUT score was correlated with the PNI, NRI, and NLR (*r* = −0.780, *r* = −0.199, and *r* = 0.304, respectively). In addition, the PNI was significantly correlated with NRI and NLR (*r* = 0.165, *p* = 0.018 and *r* = −0.272, *p* \< 0.001) and the NRI with BMI (*r* = 0.861, *p* \< 0.001) ([Supplementary Table S3](#app1-nutrients-11-01456){ref-type="app"}).

3.3. Comparison of Different Nutritional Indices According to Lupus Nephritis Subclasses {#sec3dot3-nutrients-11-01456}
----------------------------------------------------------------------------------------

Next, this study compared whether there was any difference in the nutritional indices included based on LN subclasses. The patients with pure class IV LN had a significantly higher CONUT score than patients with pure class III and V LN, as well as those with mixed class V LN. In addition, the PNI was significantly lower in patients with pure class IV LN than in those with class II and pure class III LN ([Figure 1](#nutrients-11-01456-f001){ref-type="fig"}). Furthermore, patients with pure class III and class IV LN had a higher NLR than those with pure class V nephritis. However, no significant difference was found regarding the NRI and BMI according to LN classes ([Figure 1](#nutrients-11-01456-f001){ref-type="fig"}). On the other hand, among the 5 nutritional indices included, only PNI was capable of predicting ESRF (area under the ROC curve = 0.671, sensitivity 90.0%, specificity 46.0%, 95% confidence interval (CI) 0.602--0.734, *p* = 0.002), and the optimal cut-off of PNI in predicting ESRF was determined to be PNI ≤35.41 ([Figure 2](#nutrients-11-01456-f002){ref-type="fig"}).

3.4. Factors Associated with End-stage Renal Failure in Patients with Lupus Nephritis {#sec3dot4-nutrients-11-01456}
-------------------------------------------------------------------------------------

This study performed a Cox-proportional hazard analysis to elucidate the factors associated with ESRF. In univariable analysis, the platelet and lymphocyte count, creatinine, GFR, chronicity index, PNI, and NLR were significantly associated with ESRF. However, in multivariable analysis, only creatinine (odds ratio (OR) 1.623, 95% CI 1.322--1.993, *p* \< 0.001), chronicity index (OR 1.458, 95% CI 1.203--1.767, *p* \< 0.001), and PNI (OR 0.925, 95% CI 0.865--0.989, *p* = 0.022) were independent factors for ESRF ([Table 3](#nutrients-11-01456-t003){ref-type="table"}). The Kaplan-Meier analysis also revealed that patients with a low PNI had a significantly higher probability of having ESRF than those with a high PNI (log rank test *p* = 0.003) ([Figure 3](#nutrients-11-01456-f003){ref-type="fig"}).

4. Discussion {#sec4-nutrients-11-01456}
=============

To the best of the authors knowledge, the present study is the first to evaluate the clinical significance of 5 different nutritional indices in patients with LN. Among the included indices, the CONUT score and PNI were better correlated with SLE disease activity-related measures to assess disease activity in LN. However, only the PNI was significantly lower in patients with ESRF at LN diagnosis. On the Cox-proportional hazard analysis, the PNI was an independent predictor of ESRF along with creatinine and chronicity index. Our observations imply that among the nutritional indices, the CONUT score and PNI could be useful to assess disease activity. However, only PNI was seen to have prognostic implications in identifying patients with LN at a high risk of developing ESRF.

The findings of our study indicate that the CONUT score and PNI could be useful markers to assess both global and localized disease activity in patients with LN. Notably, the correlation analysis between nutritional indices and SLE activity-related measures revealed that the CONUT score and PNI were better correlated with the SLEDAI-2K, which is the most widely used index to assess global SLE disease activity, along with WBC and platelet counts, C3, C4, and anti-dsDNA levels, urinary P/Cr ratio (which is a laboratory component of the SLEDAI-2K), and the activity index as determined through renal biopsy. Moreover, in patients with pure class IV LN, which is the most devastating form of LN, the CONUT score and PNI were found to be significantly different compared to those of other subclasses.

The CONUT score and PNI were first developed to estimate undernutrition and the risk of postoperative complications in patients with gastrointestinal cancers, respectively. However, accumulating evidences have identified that they are also associated with the prognosis of patients with other malignancies and disorders related to malnourishment \[[@B25-nutrients-11-01456],[@B26-nutrients-11-01456],[@B27-nutrients-11-01456],[@B28-nutrients-11-01456]\]. The association of the CONUT score and PNI with SLE disease activity at LN diagnosis that was found in this study could be explained by the fact that both indices are calculated using the lymphocyte count in the peripheral blood and serum albumin level. Albumin is a negative acute phase protein that could decrease in proportion to systemic inflammatory response and the hallmark of LN is proteinuria \[[@B29-nutrients-11-01456]\]. Therefore, it is possible that both systemic and localized inflammation could contribute to the development of hypoalbuminemia. Moreover, lymphopenia has been included as a hematologic criterion according to the 1997 ACR and 2012 SLE International Collaborating Clinics SLE criteria \[[@B15-nutrients-11-01456],[@B30-nutrients-11-01456]\] and has been reported to be associated with SLE disease activity and prognosis \[[@B31-nutrients-11-01456]\]. Similar findings were found in previous studies in which PNI was significantly correlated with SLE disease activity independent of other factors, supporting the results of our study \[[@B32-nutrients-11-01456],[@B33-nutrients-11-01456]\].

Owing to the poor prognosis of LN, numerous attempts have been made to evaluate the prognostic factors associated with LN. Regarding histopathological factors, the presence of proliferative LN and higher activity and chronicity indices at diagnosis have been proposed to be associated with a poor prognosis \[[@B34-nutrients-11-01456]\]. Contreras et al., and Singh et al., also demonstrated that higher creatinine and chronicity index was a predictor of poor prognosis in LN \[[@B35-nutrients-11-01456],[@B36-nutrients-11-01456]\]. Notably, our data revealed that the PNI was an independent factor associated with ESRF in multivariate Cox-proportional hazard analysis, along with creatinine and chronicity index in renal biopsy during the follow-up period. Additionally, the renal survival rate in patients with low PNI was significantly lower than those with high PNI, implying that PNI could provide additional information regarding the prediction of ESRF in LN. However, the authors found that the presence of proliferative LN and activity index were not significantly associated with ESRF, which could be associated with the disease-modulating effect of the immunosuppressive agents administered.

Among nutritional indices included, our study indicated that only PNI was capable of assessing renal outcome in patients with LN. Surprisingly, because the CONUT score had the highest correlation with SLEDAI-2K and laboratory variables included in SLEDAI-2K at baseline, the association between PNI and ESRF, instead of the CONUT score, was rather unexpected. However, the discordant results between disease activity and the development of ESRF could be attributed to the fact that baseline disease activity is not a predictive factor for patient prognosis in SLE \[[@B37-nutrients-11-01456]\]. In contrast, it has been reported that persistent proteinuria, which could lead to hypoalbuminemia as a consequence of albumin loss, as well as the serum albumin level itself, were indicative of renal outcomes in LN \[[@B38-nutrients-11-01456],[@B39-nutrients-11-01456],[@B40-nutrients-11-01456]\]. Compared to the CONUT score in which a relatively equal weighting is given between serum albumin, lymphocyte count, and total cholesterol level, the PNI is mainly dependent on the serum albumin level. Considering the importance of the serum albumin level in LN, it could be reasoned that the PNI could serve as a more appropriate measure to assess renal outcomes than the CONUT score.

In the treatment of proliferative LN, current guidelines recommend treating patients with induction therapy using either cyclophosphamide or mycophenolate mofetil, followed by sustained maintenance therapy with mycophenolate mofetil or azathioprine \[[@B4-nutrients-11-01456]\]. When this study compared the treatment between patients with ESRF and without, there were no significant differences in the proportion of patients treated with glucocorticoids, cyclophosphamide, mycophenolate mofetil, and azathioprine, suggesting that the selection of induction and maintenance treatment might not have substantially affected the patients' clinical outcomes.

BMI is the most widely used measure to assess obesity in the general population. A previous study has indicated that the prevalence of obesity in patients with SLE was reported to range from 28--50% \[[@B41-nutrients-11-01456]\]. Similar findings were noted in our study population, as the proportion of overweight patients (36.2%) was not significantly different. Interestingly, several reports have suggested that obesity is associated with disease development and poor outcomes in patients with autoimmune diseases. Previous studies have shown that obesity was associated with an increased risk of RA, SLE, and psoriatic arthritis (PsA) \[[@B42-nutrients-11-01456],[@B43-nutrients-11-01456],[@B44-nutrients-11-01456]\]. In addition, it has been suggested that increased weight was related to a lower possibility of sustained remission in patients with early RA and was related to higher disease activity and diminished clinical response in patients with PsA \[[@B45-nutrients-11-01456],[@B46-nutrients-11-01456]\]. Obesity has also been suggested to be associated with an increased risk of cardiovascular disease in patients with SLE \[[@B47-nutrients-11-01456]\]. Although first recognized solely as a measure of body composition, obesity is now regarded as a mild chronic inflammatory state that could affect the immune system via adipose-derived inflammation. In addition, previous studies have suggested that high BMI is associated with increased proteinuria and albuminuria \[[@B48-nutrients-11-01456]\]. Accordingly, a significant correlation was observed between BMI, CRP, and urinary P/Cr ratio in the present study. However, in this study, BMI itself did not correlate with SLEDAI-2K and the proportion of patients developing ESRF during the follow-up did not differ between the groups, implying that BMI may not be an appropriate measure to assess disease activity and the risk of ESRF in LN.

The strength of this study is that, to the best of the authors' knowledge, this is the first study that evaluated the clinical significance of different nutritional indices in patients with LN. However, several limitations were also present in our study. First, the assessment of clinical and laboratory data was performed by reviewing patients' medical records. Second, the number of patients with ESRF included was relatively small. Third, serial changes in the nutritional indices were not assessable and the adjustment for treatment was not possible owing to the retrospective study design. Fourth, it remains uncertain if albumin replacement therapy could be beneficial in improving the prognosis in patients with LN. Additional studies are required to validate our findings and reveal the association between nutritional status and patient prognosis in LN.

5. Conclusions {#sec5-nutrients-11-01456}
==============

In conclusion, the authors have demonstrated that among the nutritional indices examined in this study, the CONUT score and PNI were better correlated with disease activity and the PNI was associated with ESRF in patients with LN. Both the CONUT score and PNI could be useful measures to assess disease activity; in particular, PNI may provide useful information in stratifying patients at high risk of ESRF in LN.

The following are available online at <https://www.mdpi.com/2072-6643/11/7/1456/s1>, Table S1. Calculation of the CONUT score, Table S2. Comparison of medications administered in patients with and without end stage renal failure during the follow-up, Table S3. Correlation analysis between nutritional indices at lupus nephritis diagnosis.

###### 
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###### 

The baseline characteristics of patients at lupus nephritis diagnosis.

  ------------------------------------------------------------------------------------------------------------------------------
  Variables                            Total\                    Patients with ESRF\       Patients without ESRF\    *p*-value
                                       (*n* = 207)               (*n* = 20)                (*n* = 187)               
  ------------------------------------ ------------------------- ------------------------- ------------------------- -----------
  **Demographic data**                                                                                               

  Age, years                           36.0 (27.0--46.0)         37.5 (32.5--51.0)         36.0 (26.0--46.0)         0.210

  Female sex, *n* (%)                  186 (89.9)                19 (95.0)                 167 (89.3)                0.700

  Follow-up duration, months           57.1 (17.5--90.8)         33.3 (9.9--82.9)          59.2 (19.7--93.6)         0.214

  **SLE activity-related measures**                                                                                  

  SLEDAI-2K                            9.0 (7.0--12.0)           9.0 (5.0--11.0)           9.0 (7.0--13.0)           0.079

  WBC count (/mm^3^)                   4560.0 (3337.5--6805.0)   4390.0 (2795.0--7755.0)   4560.0 (3372.5--6650.0)   0.767

  Platelet count (×1000/mm^3^)         205.0 (138.3--251.8)      183.5 (68.5--222.0)       207.0 (145.8--254.0)      0.036

  Complement 3, mg/dL                  45.6 (29.5--69.1)         42.1 (27.5--59.5)         45.9 (29.6--70.8)         0.374

  Complement 4, mg/dL                  6.2 (3.2--13.3)           6.8 (3.8--12.7)           6.2 (3.1--13.3)           0.995

  Anti-dsDNA (IU/mL)                   174.8 (10.3--379.0)       25.0 (0.0--245.2)         196.9 (20.3--379.0)       0.042

  Urinary P/Cr ratio                   2.9 (1.5--6.1)            4.2 (1.5--6.9)            2.8 (1.5--5.9)            0.422

  **Clinical features, *n* (%)**                                                                                     

  Skin rash                            55 (26.6)                 4 (20.0)                  51 (27.3)                 0.601

  Photosensitivity                     14 (6.8)                  0 (0.0)                   14 (7.5)                  0.370

  Oral ulcer                           22 (10.6)                 1 (5.0)                   21 (11.2)                 0.702

  Arthritis                            11 (5.3)                  0 (0.0)                   11 (5.9)                  0.605

  Serositis                            48 (23.2)                 6 (30.0)                  42 (22.5)                 0.449

  Neurologic disorder                  2 (1.0)                   0 (0.0)                   2 (1.1)                   0.999

  Hematologic disorder                 179 (86.5)                18 (90.0)                 161 (86.1)                0.999

  Immunologic disorder                 183 (88.4)                17 (85.0)                 166 (88.8)                0.710

  **Laboratory data**                                                                                                

  Lymphocyte count (/mm^3^)            900.0 (602.5--1260.0)     655.0 (330.0--1070.0)     940.0 (610.0--1270.0)     0.012

  ESR (mm/h)                           48.0 (26.0--75.0)         46.0 (28.0--66.5)         48.0 (26.0--75.0)         0.867

  CRP (mg/L)                           2.3 (1.0--7.3)            4.7 (1.7--15.8)           2.3 (1.0--6.3)            0.061

  Cr (mg/dL)                           0.8 (0.6--1.1)            1.6 (0.9--3.6)            0.8 (0.6--1.1)            \<0.001

  GFR (CKD-EPI),\                      94.0 (64.3--115.0)        38.5 (17.0--73.5)         100.0 (69.0--117.0)       \<0.001
  mL/min/1.73 m^2^                                                                                                   

  Total cholesterol (mg/dL)            196.0 (159.3--243.8)      220.0 (185.0--234.5)      195.0 (156.0--245.8)      0.557

  Serum albumin (g/dL)                 2.9 (2.3--3.4)            2.5 (2.1--3.1)            2.9 (2.3--3.4)            0.067

  AST (IU/L)                           21.0 (17.0--35.5)         26.0 (16.5--44.5)         21.0 (17.0--34.0)         0.366

  ALT (IU/L)                           16.0 (10.0--25.0)         15.0 (9.5--30.0)          16.0 (10.0--25.0)         0.684

  **Renal biopsy data**                                                                                              

  **Lupus nephritis class, *n* (%)**                                                                                 

  Class I                              3 (1.4)                   0 (0.0)                   3 (1.6)                   0.999

  Class II                             8 (3.9)                   0 (0.0)                   8 (4.3)                   0.999

  Pure class III                       49 (23.7)                 5 (25.0)                  44 (23.5)                 0.883

  Pure class IV                        92 (44.4)                 13 (65.0)                 79 (42.2)                 0.052

  Pure class V                         23 (11.1)                 1 (5.0)                   22 (11.8)                 0.706

  Mixed class V                        31 (105.0)                0 (0.0)                   31 (16.6)                 0.049

  Class V + II                         1 (0.5)                   0 (0.0)                   1 (0.5)                   

  Class V + III                        21 (10.1)                 0 (0.0)                   21 (11.2)                 

  Class V + IV                         9 (4.3)                   0 (0.0)                   9 (4.8)                   

  Class VI                             1 (0.5)                   1 (5.0)                   0 (0.0)                   0.097

  **Activity/Chronicity index**                                                                                      

  Activity index                       7.0 (2.0--11.0)           8.5 (4.5--12.0)           7.0 (2.0--11.0)           0.126

  Chronicity index                     1.0 (1.0--2.0)            2.0 (1.5--5.0)            1.0 (1.0--2.0)            \<0.001

  **Nutritional indices**                                                                                            

  CONUT score                          4.0 (3.0--5.0)            4.5 (4.0--5.5)            4.0 (3.0--5.0)            0.173

  PNI                                  33.9 (26.7--39.3)         31.1 (23.7--34.1)         34.7 (27.0--39.9)         0.012

  NRI                                  48.8 (44.4--53.2)         49.8 (44.5--53.8)         48.7 (44.4--53.0)         0.584

  NLR                                  3.7 (2.1--6.7)            4.7 (2.4--12.4)           3.6 (2.1--6.3)            0.070

  BMI                                  21.9 (20.0--24.0)         22.4 (20.1--25.1)         21.8 (19.9--23.9)         0.595
  ------------------------------------------------------------------------------------------------------------------------------

The values are expressed as the median (interquartile range) or *n* (%). ESRF, End-stage renal failure; SLE, Systemic lupus erythematosus; SLEDAI-2K, Systemic lupus erythematosus disease activity index-2000; WBC, White blood cell; P/Cr, Protein/creatinine; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; Cr, Creatinine; GFR, Glomerular filtration rate; CKD-EPI, Chronic kidney disease epidemiology collaboration; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; CONUT, Controlling nutritional status; PNI, Prognostic nutritional index; NRI, Nutritional risk index; NLR, Neutrophil to lymphocyte ratio; BMI, Body mass index.
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###### 

Correlation analysis between variables and nutritional indices at lupus nephritis diagnosis

  ------------------------------------------------------------------------------------------------------------------------------
  Variables                           CONUT Score        PNI                NRI              NLR                BMI
  ----------------------------------- ------------------ ------------------ ---------------- ------------------ ----------------
  **SLE activity-related measures**                                                                             

  SLEDAI-2K                           0.467 (\<0.001)    −0.356 (\<0.001)   −0.183 (0.008)   −0.091 (0.192)     −0.088 (0.206)

  WBC count (/mm^3^)                  −0.264 (\<0.001)   0.205 (0.003)      0.053 (0.449)    0.548 (\<0.001)    0.089 (0.200)

  Platelet count\                     −0.329 (\<0.001)   0.260 (\<0.001)    0.063 (0.371)    0.072 (0.302)      −0.002 (0.978)
  (×1000/mm^3^)                                                                                                 

  Complement 3, mg/dL                 −0.502 (\<0.001)   0.377 (\<0.001)    0.138 (0.047)    0.058 (0.403)      0.086 (0.217)

  Complement 4, mg/dL                 −0.335 (\<0.001)   0.223 (0.001)      0.083 (0.236)    0.052 (0.454)      0.024 (0.737)

  Anti-dsDNA (IU/mL)                  0.278 (\<0.001)    −0.144 (0.038)     −0.046 (0.508)   −0.089 (0.201)     0.007 (0.919)

  Urinary P/Cr ratio                  0.221 (0.001)      −0.515 (\<0.001)   0.031 (0.655)    0.064 (0.361)      0.151 (0.030)

  **Laboratory data**                                                                                           

  Lymphocyte count (/mm^3^)           −0.662 (\<0.001)   0.549 (\<0.001)    0.102 (0.145)    −0.400 (\<0.001)   0.057 (0.413)

  ESR (mm/hr)                         0.101 (0.148)      −0.105 (0.134)     −0.095 (0.173)   −0.109 (0.119)     −0.090 (0.198)

  CRP (mg/L)                          0.246 (\<0.001)    −0.141 (0.043)     0.059 (0.401)    0.166 (0.017)      0.137 (0.049)

  Cr (mg/dL)                          0.109 (0.118)      −0.153 (0.028)     0.021 (0.762)    0.097 (0.166)      0.100 (0.153)

  GFR (CKD-EPI),\                     −0.042 (0.550)     0.118 (0.090)      −0.130 (0.062)   −0.084 (0.228)     −0.216 (0.002)
  mL/min/1.73 m^2^                                                                                              

  Total cholesterol\                  −0.133 (0.056)     −0.274 (\<0.001)   0.091 (0.192)    0.144 (0.038)      0.165 (0.018)
  (mg/dL)                                                                                                       

  Serum albumin (g/dL)                −0.611 (\<0.001)   0.922 (\<0.001)    0.147 (0.034)    −0.135 (0.053)     −0.055 (0.433)

  AST (IU/L)                          0.191 (0.006)      −0.097 (0.164)     −0.091 (0.190)   0.010 (0.887)      −0.111 (0.110)

  ALT (IU/L)                          0.037 (0.597)      0.031 (0.658)      0.002 (0.981)    0.032 (0.646)      −0.034 (0.631)

  **Renal biopsy data**                                                                                         

  Activity index                      0.188 (0.007)      −0.215 (0.002)     −0.007 (0.921)   0.072 (0.302)      0.053 (0.448)
  ------------------------------------------------------------------------------------------------------------------------------

The data are shown in correlation coefficient followed by *p*-value in parentheses. CONUT, Controlling nutritional status; PNI, Prognostic nutritional index; NRI, Nutritional risk index; NLR, Neutrophil to lymphocyte ratio; BMI, Body mass index; SLE, Systemic lupus erythematosus; SLEDAI-2K, Systemic lupus erythematosus disease activity index-2000; WBC, White blood cell; P/Cr, Protein/creatinine; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; Cr, Creatinine; GFR, Glomerular filtration rate; CKD-EPI, Chronic kidney disease epidemiology collaboration; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase.
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###### 

The Cox-proportional hazard analysis of variables associated with end-stage renal failure during the follow-up.

  ----------------------------------------------------------------------------------------------------------------------------------
                                          Univariable Analysis   Multivariable Analysis                                    
  --------------------------------------- ---------------------- ------------------------ --------- ------- -------------- ---------
  SLEDAI-2K                               0.904                  0.803--1.016             0.091                            

  WBC count (/mm^3^)                      1.000                  0.999--1.000             0.744                            

  Platelet count (×1000/mm^3^)            0.993                  0.987--0.999             0.015                            

  Complement 3, mg/dL                     0.992                  0.974--1.010             0.362                            

  Complement 4, mg/dL                     0.995                  0.938--1.054             0.853                            

  Anti-dsDNA (IU/mL)                      0.998                  0.995--1.000             0.063                            

  Urinary P/Cr ratio                      1.078                  0.964--1.206             0.185                            

  Lymphocyte count (/mm^3^)               0.999                  0.998--0.999             0.023                            

  ESR (mm/h)                              1.000                  0.986--1.014             0.999                            

  CRP (mg/L)                              1.012                  0.999--1.025             0.070                            

  Cr (mg/dL)                              1.827                  1.522, 2.193             \<0.001   1.623   1.322--1.993   \<0.001

  GFR (CKD-EPI),\                         0.959                  0.944, 0.975             \<0.001                          
  mL/min/1.73 m^2^                                                                                                         

  Total cholesterol (mg/dL)               0.999                  0.994--1.006             0.977                            

  Serum albumin (g/dL)                    0.569                  0.311--1.041             0.067                            

  AST (IU/L)                              1.002                  0.996--1.009             0.491                            

  ALT (IU/L)                              0.999                  0.986--1.014             0.979                            

  Pure proliferative lupus nephritis^¶^   4.300                  0.998--18.534            0.050                            

  Activity index                          1.076                  0.989--1.171             0.089                            

  Chronicity index                        1.493                  1.254--1.778             \<0.001   1.458   1.203--1.767   \<0.001

  CONUT score                             1.230                  0.957--1.582             0.106                            

  PNI                                     0.932                  0.880--0.987             0.017     0.925   0.865--0.989   0.022

  NRI                                     1.007                  0.959--1.057             0.789                            

  NLR                                     1.070                  1.020--1.122             0.006                            

  BMI                                     1.029                  0.908--1.167             0.651                            
  ----------------------------------------------------------------------------------------------------------------------------------

^¶^Proliferative lupus nephritis was defined as either class III or IV lupus nephritis according to the International Society of Nephrology/ Renal Pathology Society criteria. SLEDAI-2K, Systemic lupus erythematosus disease activity index-2000; WBC, White blood cell; P/Cr, Protein/creatinine; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; Cr, Creatinine; GFR, Glomerular filtration rate; CKD-EPI, Chronic kidney disease epidemiology collaboration; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; CONUT, Controlling nutritional status; PNI, Prognostic nutritional index; NRI, Nutritional risk index; NLR, Neutrophil to lymphocyte ratio; BMI, Body mass index.
